PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29545894-6 2018 In TNBS mice receiving AdTGF-2, the increase in IFN-gamma, tumor necrosis factor-alpha, IL-6, IL-17 and IL-23 was significantly prevented by dexamethasone treatment. Trinitrobenzenesulfonic Acid 3-7 interleukin 6 Mus musculus 88-92 25698557-6 2015 Oral administration of AIII and sarsasapogenin inhibited 2,3,4-trinitrobenzene sulfonic acid (TNBS)-induced colon shortening and myeloperoxidase activity in mice, along with reducing NF-kappaB activation and interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6 levels, while simultaneously increasing IL-10. Trinitrobenzenesulfonic Acid 94-98 interleukin 6 Mus musculus 271-275 28164167-8 2016 Following TNBS treatment, IL-6 and artemin mRNA levels were decreased in the distal colon of NMS mice, despite increased MPO activity. Trinitrobenzenesulfonic Acid 10-14 interleukin 6 Mus musculus 26-30 26926174-10 2016 In addition, neomangiferin inhibited TNBS-induced expression of tumor necrosis factor-alpha, IL-17, IL-6, and IL-1beta, and increased IL-10 expression. Trinitrobenzenesulfonic Acid 37-41 interleukin 6 Mus musculus 100-104 26561804-5 2015 Additionally, ELISA showed that the serum levels of IFN-gamma, TNF-alpha, IL-12, IL-6, and IL-1beta were down-regulated in a TNBS model of colitis. Trinitrobenzenesulfonic Acid 125-129 interleukin 6 Mus musculus 81-85 26241646-9 2015 TNBS-induced influx of T-cells and inflammatory monocytes into the colon was higher in Nur77-/- mice, along with increased expression of MCP-1, TNFalpha and IL-6, and decreased Foxp3 RNA expression, compared to wild-type mice. Trinitrobenzenesulfonic Acid 0-4 interleukin 6 Mus musculus 157-161 28955241-12 2017 Moreover, TNBS instillation enhanced local synthesis of inflammatory mediators associated with a neutrophilic response, i.e., CXCL1, CXCL2, and interleukin-6. Trinitrobenzenesulfonic Acid 10-14 interleukin 6 Mus musculus 144-157 25213465-9 2014 Ursolic acid (20 mg/kg) also inhibited TNBS-induced IL-1beta, IL-6, TNF-alpha by 93, 86, and 85%, respectively (p < 0.05). Trinitrobenzenesulfonic Acid 39-43 interleukin 6 Mus musculus 62-66 17077645-6 2006 METHODS: Acute colitis was induced in wild-type and IL-6-deficient (Il-6(-/-)) mice by intracolonic administration of TNBS. Trinitrobenzenesulfonic Acid 118-122 interleukin 6 Mus musculus 68-72 24815859-6 2014 CLP-0611 also inhibited TNBS-induced expression of TNF-alpha, IL-1beta, and IL-6. Trinitrobenzenesulfonic Acid 24-28 interleukin 6 Mus musculus 76-80 24524998-8 2014 However, 5-HT combined with a low dose of 2,4,6-trinitrobenzene sulfonic acid (TNBS), the level of which caused a minimal level of colitis, exaggerated colon inflammation accompanied by much more enhanced induction of inflammatory cytokines, IL-6, IL-8, and MCP-1, indicating that colon epithelial cells directly exposed to 5-HT are primed toward inflammation. Trinitrobenzenesulfonic Acid 42-77 interleukin 6 Mus musculus 242-246 24524998-8 2014 However, 5-HT combined with a low dose of 2,4,6-trinitrobenzene sulfonic acid (TNBS), the level of which caused a minimal level of colitis, exaggerated colon inflammation accompanied by much more enhanced induction of inflammatory cytokines, IL-6, IL-8, and MCP-1, indicating that colon epithelial cells directly exposed to 5-HT are primed toward inflammation. Trinitrobenzenesulfonic Acid 79-83 interleukin 6 Mus musculus 242-246 23375938-10 2013 Arctigenin inhibited TNBS-induced IL-1beta, TNF-alpha and IL-6 expression, as well as PI3K, AKT and IKKbeta phosphorylation and NF-kappaB activation in mice, but increased IL-10 and CD204 expression. Trinitrobenzenesulfonic Acid 21-25 interleukin 6 Mus musculus 58-62 20546811-8 2010 The tumor necrosis factor-alpha, interleukin-6, and nitric oxide synthase 2 mRNA content of both liver and skeletal muscle was increased in TNBS-treated mice; and plasma tumor necrosis factor-alpha and interleukin-6 concentrations were also elevated. Trinitrobenzenesulfonic Acid 140-144 interleukin 6 Mus musculus 33-46 20546811-8 2010 The tumor necrosis factor-alpha, interleukin-6, and nitric oxide synthase 2 mRNA content of both liver and skeletal muscle was increased in TNBS-treated mice; and plasma tumor necrosis factor-alpha and interleukin-6 concentrations were also elevated. Trinitrobenzenesulfonic Acid 140-144 interleukin 6 Mus musculus 202-215 19443690-10 2009 We also found that supernatants from NT-exposed 3T3-L1-NTR1 preadipocytes and mesenteric fat obtained from wild-type mice 2 days after TNBS administration stimulate an IL-6-dependent macrophage migration measured by a macrophage migration assay, whereas this response is reduced when mesenteric fat from NT KO mice is used. Trinitrobenzenesulfonic Acid 135-139 interleukin 6 Mus musculus 168-172 19050899-6 2009 Intrarectal treatment of TNBS in mice caused colon shortening and also increased colonic expression of IL-1beta, IL-6, and TNF-alpha expression. Trinitrobenzenesulfonic Acid 25-29 interleukin 6 Mus musculus 113-117 19067146-5 2009 The TNBS treatment caused colon shortening, increased myeloperoxidase activity, induced IL-1beta, TNF-alpha, and IL-6 expression in the colon, activated NF-kappaB, and potentiated the GAG-degrading activities of intestinal microflora. Trinitrobenzenesulfonic Acid 4-8 interleukin 6 Mus musculus 113-117 17077645-0 2006 Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice. Trinitrobenzenesulfonic Acid 45-74 interleukin 6 Mus musculus 0-13 17077645-6 2006 METHODS: Acute colitis was induced in wild-type and IL-6-deficient (Il-6(-/-)) mice by intracolonic administration of TNBS. Trinitrobenzenesulfonic Acid 118-122 interleukin 6 Mus musculus 52-56 24912557-5 2014 Expressions of the IL-6 and FasL genes appeared to be down-regulated by the formulation in TNBS-treated colon tissues, suggesting that the suppression of those genes may be involved in the anti-inflammatory activity of the formulation. Trinitrobenzenesulfonic Acid 91-95 interleukin 6 Mus musculus 19-23 23742179-8 2013 Treatment with TNBS caused colon shortening; increased myeloperoxidase activity; and increased IL-1beta, IL-6 and TNF-alpha expression in mice. Trinitrobenzenesulfonic Acid 15-19 interleukin 6 Mus musculus 105-109 19924809-8 2010 Serum LBP increased in WT mice following TNBS administration, in conjunction with increased serum TNF-alpha, IL-6, and IL-10, and expansion of regulatory T-cell numbers. Trinitrobenzenesulfonic Acid 41-45 interleukin 6 Mus musculus 109-113 19956958-5 2010 RESULT: Intrarectal treatment of TNBS in mice caused colon shortening and also increased colonic expression of IL-1beta, IL-6, and TNF-alpha expression. Trinitrobenzenesulfonic Acid 33-37 interleukin 6 Mus musculus 121-125 19693649-5 2009 Upon treatment with hyper-IL-6, IRF4(-/-) mice lost their protective properties towards TNBS application. Trinitrobenzenesulfonic Acid 88-92 interleukin 6 Mus musculus 26-30 16771773-3 2006 After the induction of inflammation with TNBS, the levels of proinflammatory cytokines, such as TNF-alpha, interleukin-1beta and interleukin-6, were elevated both in the inflamed mucosa and muscle layers in the wild-type mice; however, the productions of these cytokines were greatly reduced in the TNF-alpha(-/-) mouse colon. Trinitrobenzenesulfonic Acid 41-45 interleukin 6 Mus musculus 129-142 17077645-8 2006 RESULTS: In wild-type mice, TNBS administration increased both IL-6 serum levels and local expression of IL-6 by 36 and 9 fold, respectively, compared with control, vehicle-injected mice. Trinitrobenzenesulfonic Acid 28-32 interleukin 6 Mus musculus 63-67 17077645-8 2006 RESULTS: In wild-type mice, TNBS administration increased both IL-6 serum levels and local expression of IL-6 by 36 and 9 fold, respectively, compared with control, vehicle-injected mice. Trinitrobenzenesulfonic Acid 28-32 interleukin 6 Mus musculus 105-109 17077645-9 2006 Compared with the wild-type mice, the Il-6(-/-) mice had significantly reduced intestinal inflammation as evidenced by epithelial damage, neutrophil infiltration, colon thickness and proinflammatory cytokine expression, following treatment with TNBS. Trinitrobenzenesulfonic Acid 245-249 interleukin 6 Mus musculus 38-42 11113077-9 2000 Treatment of animals with neutralizing anti-IL-6 antibody reduced the TNBS-induced growth and activation of the adrenal cortices. Trinitrobenzenesulfonic Acid 70-74 interleukin 6 Mus musculus 44-48